Show simple item record

dc.contributor.authorRivera Díaz, R.
dc.contributor.authorPozo, T.
dc.contributor.authorAlfageme, F.
dc.contributor.authorDíaz Ley, B.
dc.contributor.authorOsorio, G. F.
dc.contributor.authorChico, R.
dc.contributor.authorVilarrasa, E.
dc.contributor.authorSilvente, C.
dc.contributor.authorCiudad Blanco, C.
dc.contributor.authorRomaní, J.
dc.contributor.authorMartorell, A.
dc.contributor.authorFernández, P.
dc.contributor.authorRomero Ferreiro, Carmen
dc.contributor.authorMolina Leyva, A.
dc.description.abstractBackground Hidradenitis suppurativa (HS) is a chronic skin condition causing lesions in which high levels of interleukin (IL)-23 and T-helper 17 cells are found. Adalimumab remains the only approved treatment. Guselkumab, an antibody targeting the p19 protein subunit of extracellular IL-23, is approved for the treatment of moderate–severe psoriasis, but evidence on its efficacy in treating HS is limited. Objectives To assess the effectiveness and safety of guselkumab in treating moderate–severe HS under clinical practice conditions. Methods A multicentre retrospective observational study was carried out in 13 Spanish Hospitals including adult HS patients treated with guselkumab within a compassionate use programme (March 2020–March 2022). Data referred to patient demographic and clinical characteristics at treatment initiation (baseline), patient-reported outcomes (Numerical Pain Rating Scale [NPRS] and Dermatology Life Quality Index [DLQI]), physician scores (International Hidradenitis Suppurativa Severity Score System [IHS4], HS Physical Global Score [HS-PGA] and Hidradenitis Suppurativa Clinical Response [HiSCR]) were recorded at baseline and at 16, 24, and 48 weeks of treatment. Results A total of 69 patients were included. Most (84.10%) had severe HS (Hurley III) and had been diagnosed for over ten years (58.80%). The patients had been subjected to multiple non-biological (mean 3.56) or biological (mean 1.78) therapies, and almost 90% of those treated with biologics had received adalimumab. A significant decrease in IHS4, HS-PGA, NPRS, and DLQI scores was observed from baseline to 48 weeks of guselkumab treatment (all p < 0.01). HiSCR was achieved in 58.33% and 56.52% of the patients at 16 and 24 weeks, respectively. Overall, 16 patients discontinued treatment, mostly due to inefficacy (n = 7) or loss of efficacy (n = 3). No serious adverse events were observed. Conclusions Our results indicate that guselkumab may be a safe and effective therapeutic alternative for patients with severe HS that fail to respond to other
dc.publisherActas Dermo-Sifiliográficasspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.subjectHidradenitis suppurativaspa
dc.subjectReal-world evidencespa
dc.titleThe Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective
dc.typejournal articlespa
dc.rights.accessRightsopen accessspa
dc.description.extent661 KBspa

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España